Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study

Among the multitude of complaints related to the lowering of estrogen in the menopause, those affecting the genitourinary tract are reported by at least 50% of menopausal women [1 –4]. The most common signs and symptoms of vulvovaginal atrophy (VVA) are dryness, dyspareunia, redness, itching, with occasional discharge and/or bleeding [5]. Recently, genitourinary syndrome of menopause (GSM) is a new definition to encompass even other sexual and urinary symptoms associated wi th VVA[6].

Source: Maturitas - March 4, 2021 Category: Primary Care Authors: Francesco De Seta, Salvatore Caruso, Giovanni Di Lorenzo, Federico Romano, Mariateresa Mirandola, Rossella E. Nappi Source Type: research